0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.

Slides:



Advertisements
Similar presentations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Advertisements

Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003.
MONITORING OF SUBGRANTEES
Organizational Governance
Radiopharmaceutical Production
Child Safeguarding Standards
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Buying Better Outcomes Workshop 4 Equalities and Contract Management If you do not take it seriously, why should the supplier?
QUALITY ASSURANCE AND IMPROVEMENT PROGRAM (QAIP)
Implementing SMS in Civil Aviation: the Canadian Perspective.
Developing a Records & Information Retention & Disposition Program:
Implementing and Auditing Ethics Programs
What SMS means for an Operator’s relationship with the CAA
Purpose of the Standards
RC14001 ® Update GPCA Responsible Care Committee September 23, 2013.
WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October Washington, D.C. David Davidovic,
Building a Compliance Risk Monitoring Program HCCA Compliance Institute New OrleansApril 19, 2005 Lois Dehls Cornell, Esq. Assistant Vice President, Deputy.
Control environment and control activities. Day II Session III and IV.
Internal Auditing and Outsourcing
A SOUND INVESTMENT IN SUCCESSFUL VR OUTCOMES FINANCIAL MANAGEMENT FINANCIAL MANAGEMENT.
Information Security Governance 25 th June 2007 Gordon Micallef Vice President – ISACA MALTA CHAPTER.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
What To Look For In A Coding Audit Don’t Leave Money On The Table Wiks Moffat Laurie Zabel, CHC, CHPC, CPC.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Establishing A Compliance Program: It Makes Sense
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
1 Today’s Presentation Sarbanes Oxley and Financial Reporting An NSTAR Perspective.
CERTIFICATION In the Electronics Recycling Industry © 2007 IAER Web Site - -
Health Care Compliance Association Region VII Compliance Conference August 1, 2003.
Because your patients come first. Regulatory and Practice Management Services Daniel L. Johnson, CPC, CPC-H.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress How to establish a Compliance Program that will Minimize the Impact of.
SMS Implementation Lessons Learned CTA COSCAP-NA Kim Trethewey.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
FleetBoston Financial HIPAA Privacy Compliance Agnes Bundy Scanlan Managing Director and Chief Privacy Officer FleetBoston Financial.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Connecting the Dots A Practical Approach to Integrating Compliance, Risk and Quality Jody Ann Noon RN, JD Partner Health Care Regulatory Practice.
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
DGS Recommendations to the Governor’s Task Force on Contracting & Procurement Review Report Overview August 12, 2002.
SMS Implementation Lessons Learned October th Steering Committee COSCAP-SEA, Macau 2 Sources ICAO Regional Workshop on Safety Management.
Implementing an Effective Global Anti-Bribery Program Implementing an Effective Global Anti-Bribery Program Elaine Murphy, MBA Director Health Care Compliance.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Special Program for Internal/Compliance Audit Professionals: Enterprise Risk.
Agenda for Session Compliance in Clinical Research
RECOMMENDATIONS OF THE GOVERNOR ’ S TASK FORCE ON CONTRACTING AND PROCUREMENT REVIEW Report Overview PD Customer Forum September 2002.
Copyright © 2015 Raytheon Company. All rights reserved. Customer Success Is Our Mission is a registered trademark of Raytheon Company. Fine Tuning Anti-Corruption.
Company: Cincinnati Insurance Company Position: IT Governance Risk & Compliance Service Manager Location: Fairfield, OH About the Company : The Cincinnati.
Chapter 8 Auditing in an E-commerce Environment
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Technical Assistance Office TCP Projects 2005 Contractual and Financial Management Administrative and Financial Handbook Prepared by IA, 14/12/2001 SOCRATES.
1 Building a Compliance Program in a Small Cap Company The Seventh Annual Pharmaceutical Compliance and Best Practices Forum November 9, 2006 Colleen CravenJanice.
Compliance at the Crossroads: How can the Compliance Profession Move to the Second Generation? A Practical Approach to Integrating Compliance, Risk and.
OHSAS Occupational health and safety management system.
ICAJ/PAB - Improving Compliance with International Standards on Auditing Planning an audit of financial statements 19 July 2014.
SMS Implementation Lessons Learned. 2 Sources ICAO Regional Workshop on Safety Management Systems (SMS) and State Safety Programme (SSP) Implementation.
Auditing Cloud Services
Internal and Governmental Financial Auditing and Operational Auditing
Safety Accountabilities
Построение культуры integrity в компании Aнар Каримов партнёр «ЭКВИТА»
MAC Board Effectiveness Survey
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
RECORDS AND INFORMATION
Risk Management: why and how to protect your health center
Timothy B. Cleary, Esq. Meredith Manning, Esq.
MAC Board Effectiveness Survey
Radiopharmaceutical Production
Presentation transcript:

0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Working with Third Parties, Vendors, and Strategic Partners Diana Borges Compliance Manager Teva Pharmaceuticals Paul Silver Managing Director Huron Consulting Group Brian Dahl, Esq. Director of Compliance Teva Pharmaceuticals Michele Girdharry Manager Huron Consulting Group

1 I.The Importance of Auditing & Monitoring Third-Party Vendors II.Balancing Business and Compliance Challenges When Auditing III.Criteria When Choosing a Third-Party Vendor to Audit IV.Planning The Audit V.Navigating Challenges that Arise from Audit Results VI.Capturing Compliance Requirements During the Contracting Process Agenda

The Importance of Auditing & Monitoring Third-Party Vendors

3 Monitoring & Auditing are Essential Parts of an Effective Compliance Program Pharmaceutical manufacturers are responsible for auditing and monitoring as part of an effective compliance program –One of seven elements –Corporate Integrity Agreements –NV and MA require certification that a manufacturer has conducted audits a part of its compliance program Demonstrates “proactive” vs. “reactive” action by a manufacturer PhRMA Code states that companies should periodically monitor speaker programs for compliance with FDA regulatory requirements

4 Monitoring & Auditing Responsibility Extends to Third-Party Vendors All guidance and regulations make clear that pharmaceutical manufacturers are responsible for all vendor activities that involve a healthcare professional Some Corporate Integrity Agreements are holding companies accountable for vendor activity

5 Evaluating Operational Effectiveness and Process Efficiency Identifying areas for improvement in the business processes Assist in addressing future issues up front in the contracting process Provides documentation that may be necessary when corrective action is required (e.g. termination or modification of a contract, etc) Conduct due diligence on vendors you are looking to contract or who you may have inherited through acquisition

Balancing Business and Compliance Challenges when Auditing

7 NVNV Business Unit Challenges Sense of urgency to get things done Allocating additional time and resources while managing day- to-day operational responsibilities Difficulties in taking steps to remedy findings –Entrenched vendor –Too far along in negotiations

8 NVNV Compliance Challenges Creating compliance awareness with business units Diverting resources when a business unit needs a vendor cleared Choosing appropriate resources for an audit Getting access to people / documents / systems Addressing resistance from stakeholders and business units Determining what courses of action to take with audit results

Criteria When Choosing a Third-Party Vendor to Audit

10 Areas of Risk Identified Internally at the Company Interviews with key personnel to identify risks –One-on-one sessions –Casual conversations Internal audits, QA review or Finance may discover potential vendor issues

11 Current Government Investigations and Advisory Opinions Issued by the OIG Payments to physicians Off label Promotion Transparency Consider what direction investigative and enforcement actions will take: –Advisory Opinions –Guidance provided by the FDA, DOJ and OIG –OIG Work plan

Planning the Audit

13 Scope Based on potential reasons for the audit, determine the appropriate scope: –Brand / Product / Business Unit –Activity Type –Time period

14 Identifying Audit Resources An internal audit group may have the infrastructure and relationships to efficiently manage an audit for the Company An external resource can provide an independent perspective and will have a good understanding of regulatory and compliance issues important to pharmaceutical companies. A Teaming Approach

15 Establishing a Workplan and Timeline Determine the specific areas of risk to evaluate Develop a methodology to test controls in place for each functional area or process managed by a third party vendor Develop a timeline for the audit that balances business expectations and compliance obligations (e.g. NV, MA, etc.)

16 Sample Audit Plan Controls that support risk area Audit Tests Area of Risk

Navigating Challenges That Arise from Audit Results

18 Determining Appropriate Courses of Action Prioritizing audit findings Determine what “buy-in” or approval will be needed Determine what internal resources and effort are available Responsibility for resolving issues should be assigned to the business unit –Compliance should provide guidance and oversight to the remediation plan Numerous findings may require a more comprehensive or follow-up audit Systemic findings may require modification or review of the vendor relationship

19 Determining who is Responsible for Resolving Risks Identify all key stakeholders in the business process (e.g. Business unit, Compliance, Legal, etc.) Determine who should own the responsibility in the Business unit for: –Managing the action plan –Reviewing and monitoring the action plan –Evaluating the effectiveness of action plan

20 Potentially Terminating a Contract How much has been invested in the relationship? What will be the impact on the business unit? How long will it take to choose a new vendor? How much will it cost to replace a vendor (i.e. from identifying a new vendor, to going “live”)?

Capturing Compliance Requirements During the Contracting Process: Lessons Learned

22 Considerations During the Contracting Process Teaming with Procurement to reinforce compliance Ensure vendor can comply with company policies, SOPs and Business rules –Consider requirements when co-promote partner is involved Establish a process for communicating process and management changes that must be approved by the Company Require company-specific training for vendor representatives and contractors Establish periodic auditing of program

23 Considerations During the Contracting Process Define termination provisions Establish scheduled reporting requirements for expenses and documentation (i.e. monthly, at the end of each program, etc.) Establish document retention requirements (e.g. attendee lists, copies of medical and promotional materials distributed, expense receipts, etc.) Require notification if vendor is under or comes under investigation

24 Questions? Paul Silver (678) Atlanta Office (646) New York Office Michele Girdharry (646) Brian Dahl, Esq. (816) Diana Borges (215)